Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Cell Models for Research

Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a rare autosomal dominant syndrome caused by germline mutations in the fumarate hydratase (FH) gene. The exact prevalence is unknown, but it is estimated to affect 1 in 200,000 individuals. The most significant clinical manifestation is an aggressive form of type 2 papillary renal cell carcinoma (RCC), which can metastasize early and has a poor prognosis. According to the NCI, the 5-year survival for metastatic HLRCC-associated RCC is less than 10%. Other features include cutaneous leiomyomas and uterine fibroids, often presenting in early adulthood. Early diagnosis and surveillance are critical for managing renal cancer risk.

HLRCC serves as an excellent model for studying the role of metabolic dysregulation in cancer. The loss of FH leads to accumulation of fumarate, which acts as an oncometabolite, stabilizing hypoxia-inducible factors (HIF) and promoting epithelial-mesenchymal transition (EMT). This provides a clear link between a single genetic alteration and tumorigenesis, making it ideal for mechanistic studies. Additionally, HLRCC tumors exhibit distinct molecular features, such as high levels of NRF2 activation and altered DNA methylation, which can be explored in isogenic cell models. Public datasets, including TCGA and COSMIC, provide mutation frequencies and expression profiles, enabling integrative analyses.

The loss of fumarate hydratase (FH) in HLRCC leads to accumulation of fumarate, which competitively inhibits prolyl hydroxylases (PHDs), resulting in stabilization of HIF1α and HIF2α. This triggers a pseudo-hypoxic response, upregulating genes involved in angiogenesis, glycolysis, and cell survival. Additionally, fumarate modifies cysteine residues on KEAP1, leading to NRF2 activation and antioxidant response. The accumulation of fumarate also inhibits the activity of α-ketoglutarate-dependent dioxygenases, including TET enzymes and JmjC histone demethylases, causing DNA and histone hypermethylation. These pathways collectively promote tumorigenesis and metastasis.

Data from TCGA and COSMIC.

• • HIF signaling: Stabilization of HIF1α and HIF2α leads to upregulation of VEGF, GLUT1, and PDK1.
• • NRF2 pathway: Constitutive activation due to fumarate-mediated modification of KEAP1, leading to antioxidant response and metabolic rewiring.
• • PI3K/AKT/mTOR: Enhanced signaling due to HIF-dependent growth factor receptor activation.
• • Epigenetic remodeling: Hypermethylation of histones and DNA due to inhibition of TET and JmjC enzymes.
• • EMT: Activation of TGF-β and Wnt pathways promotes epithelial-mesenchymal transition.

Organoids derived from HLRCC patient tumors are also being developed, offering a more physiologically relevant 3D model for drug testing and personalized medicine.

• • Patient-derived xenografts (PDX): Implantation of HLRCC tumor fragments into immunodeficient mice, preserving tumor heterogeneity.
• • Genetically engineered mouse models (GEMM): Conditional Fh1 knockout in renal tubules leads to renal cysts and tumors, recapitulating human disease.
• • Induced models: Use of CRISPR to introduce Fh1 mutations in mouse embryonic stem cells to generate germline models.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications. For HLRCC, knockout of FH in renal epithelial cells (e.g., RPTEC, HK-2) recapitulates the loss of function, while knock-in of specific FH mutations (e.g., p.R190H) can model dominant-negative effects. These gene-edited models are essential for studying the molecular consequences of FH loss in a controlled background. Commercially available, sequence-verified models accelerate research by providing validated tools, but it is important to select models that have been authenticated and tested for mycoplasma contamination.

Gene-edited cell lines allow functional validation of FH and other genes implicated in HLRCC. For example, FH knockout in RPTEC cells leads to increased fumarate levels, HIF stabilization, and enhanced migration, confirming its tumor suppressor role. Similarly, knock-in of FH mutations can be used to study the impact of specific variants on protein function and cellular phenotype.

Isogenic pairs (wild-type vs. FH knockout) are ideal for high-throughput drug screening to identify compounds that selectively kill FH-deficient cells. This approach has identified potential therapeutic targets such as heme oxygenase-1 (HO-1) inhibitors and PARP inhibitors. Additionally, drug resistance can be modeled by exposing FH knockout cells to increasing concentrations of drugs and selecting resistant clones.

CRISPR-based synthetic lethality screens can identify genes that are essential for survival of FH-deficient cells but not wild-type cells. These genes represent potential therapeutic targets and biomarkers. For example, a screen in FH knockout cells identified the enzyme fumarate hydratase itself as a synthetic lethal target, suggesting a potential therapeutic window.